Skip to main content

Table 1 Demographics and clinicopathologic features of 69 NSCLC patients screened for T790 M mutation

From: EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors

Variables No. of patients (%)
Gender
 Male 23(33.3)
 Female 46(66.7)
Age
  ≤ 40 5 (7.2)
  > 40 64(92.8)
ECOG performance status
 0–1 58(84.1)
 2 11(15.9)
Histologic subtype
 Adenocarcinoma 67(97.1)
 Adenosquamous carcinoma 2 (2.9)
Smoking status
 Smoker 22(31.9)
 Non-smoker 47(68.1)
TNM Stage
 IIIB 20(29.0)
 IVA 21(30.4)
 IVB 28(40.6)
M Stage
 M1a 19(38.8)
 M1b 4 (8.2)
 M1c 26(53.0)
First generation EGFR TKIs
 Gefitinib 22(31.8)
 Elortinib 15(21.7)
 Ecotinib 31(44.9)
 Two or more TKI drugs 1 (1.4)
EGFR mutation detection
 FFPE slieds by cobas 22
 cfDNA by cobas 47
 T790 M ddPCR assay 69
Total 69